It also upregulated p53 and its downstream p21 along with activating caspase-3/7 and PARP cleavage.<h4>Conclusion</h4>Our findings highlight AOH1996 as a promising therapeutic agent for NSCLC management, with potent effects on cell survival, migration, invasion, and tumour growth. The gene discussed is TP53; the disease is non-small cell lung carcinoma.